Curated News
By: NewsRamp Editorial Staff
April 30, 2025
Monogram Technologies Receives Approval for Clinical Trial in India
TLDR
- Monogram Technologies gains approval in India for clinical trial with Shalby Limited, paving the way for a major milestone and potential global orthopedic standard elevation.
- Monogram's mBôs TKA system receives approval in India for a 102-patient clinical trial evaluating safety and effectiveness in robotic total knee replacement surgeries.
- Monogram's AI-driven robotics aim to improve orthopedic surgery, offering personalized knee implants for patients and potentially raising global orthopedic standards.
- Monogram Technologies' approval for a clinical trial in India marks a significant advancement in AI-driven robotics for orthopedic surgery, shaping the future of healthcare.
Impact - Why it Matters
This news matters as it highlights a significant development in the field of orthopedic surgery, with Monogram Technologies poised to introduce its AI-driven robotics system through a multi-center clinical trial in India, potentially setting new standards for orthopedic procedures globally.
Summary
Monogram Technologies (NASDAQ: MGRM) has received approval from India’s Central Drugs Standard Control Organization to import its mBôs TKA system and begin a 102-patient clinical trial in partnership with Shalby Limited (NSE: SHALBY) to evaluate the safety and effectiveness of its robotic total knee replacement system.
CEO Benjamin Sexson called the approval a major milestone toward commercial launch, while partners from Reliance Life Sciences and Shalby praised the trial’s potential to elevate global orthopedic standards, with surgeries expected to begin within 90 business days.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Monogram Technologies Receives Approval for Clinical Trial in India
